MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Stock Information for Milestone Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Issues Complete Response Letter for Etripamil for PSVT
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.